Last reviewed · How we verify
Xiangshao Granules
Xiangshao Granules, marketed by Peking Union Medical College Hospital, is a traditional Chinese medicine with a key composition patent expiring in 2028. The drug's market position is bolstered by its unique mechanism and primary indication, which are currently undisclosed but likely contribute to its competitive edge. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Xiangshao Granules |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- the Effects of Different Therapy Regimens on Menopausal Sleep Disorders (PHASE4)
- Effects of Xiangshao Granules on Anxiety in Menopausal Women. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xiangshao Granules CI brief — competitive landscape report
- Xiangshao Granules updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI